Aflac Incorporated (NYSE:AFL) Receives $103.36 Average Target Price from Analysts

Aflac Incorporated (NYSE:AFL - Get Free Report) has earned an average rating of "Hold" from the fourteen ratings firms that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $103.36.

AFL has been the subject of several research analyst reports. Evercore ISI decreased their price objective on shares of Aflac from $104.00 to $102.00 and set an "underperform" rating for the company in a research report on Wednesday, December 4th. JPMorgan Chase & Co. increased their price target on shares of Aflac from $90.00 to $94.00 and gave the stock a "neutral" rating in a report on Tuesday, January 7th. Barclays cut their price target on shares of Aflac from $98.00 to $95.00 and set an "underweight" rating on the stock in a report on Friday, February 7th. Keefe, Bruyette & Woods cut their price target on shares of Aflac from $107.00 to $104.00 and set a "market perform" rating on the stock in a report on Wednesday, February 12th. Finally, StockNews.com upgraded shares of Aflac from a "sell" rating to a "hold" rating in a report on Friday, February 14th.

Remove Ads

Aflac Stock Up 0.2 %

Shares of AFL stock traded up $0.20 during mid-day trading on Monday, hitting $108.66. 1,744,675 shares of the stock traded hands, compared to its average volume of 1,984,445. The stock has a market cap of $59.39 billion, a P/E ratio of 11.32, a P/E/G ratio of 3.24 and a beta of 0.93. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.10 and a quick ratio of 0.08. The stock's fifty day moving average is $105.70 and its two-hundred day moving average is $107.65. Aflac has a 52-week low of $79.31 and a 52-week high of $115.50.

Aflac (NYSE:AFL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The financial services provider reported $1.56 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.07). Aflac had a net margin of 28.76% and a return on equity of 16.20%. Equities analysts predict that Aflac will post 6.88 EPS for the current year.

Insider Transactions at Aflac

In other news, Director Charles D. Lake II sold 29,802 shares of Aflac stock in a transaction on Monday, March 10th. The stock was sold at an average price of $107.29, for a total transaction of $3,197,456.58. Following the transaction, the director now owns 49,962 shares in the company, valued at $5,360,422.98. The trade was a 37.36 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Audrey B. Tillman sold 24,744 shares of Aflac stock in a transaction on Friday, December 27th. The stock was sold at an average price of $103.40, for a total value of $2,558,529.60. Following the transaction, the executive vice president now owns 222,618 shares in the company, valued at approximately $23,018,701.20. This represents a 10.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,546 shares of company stock worth $5,863,616 in the last quarter. Company insiders own 0.80% of the company's stock.

Institutional Trading of Aflac

A number of hedge funds and other institutional investors have recently modified their holdings of AFL. Whipplewood Advisors LLC acquired a new stake in shares of Aflac during the 4th quarter worth about $26,000. Darwin Wealth Management LLC acquired a new stake in shares of Aflac during the 3rd quarter worth about $34,000. BankPlus Trust Department acquired a new stake in shares of Aflac during the 4th quarter worth about $34,000. Curio Wealth LLC acquired a new position in Aflac in the 4th quarter valued at about $36,000. Finally, Raelipskie Partnership acquired a new position in Aflac in the 3rd quarter valued at about $38,000. 67.44% of the stock is owned by institutional investors and hedge funds.

Aflac Company Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.